JOHNSON & JOHNSON is 362.4x more valuable than AbCellera Biologics Inc. by market capitalization ($579.83 B vs $1.60 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ABCL | JNJ |
|---|---|---|
| Market cap | $1.60 B | $579.83 B |
| US-listed rank | #2294 | #20 |
| Revenue (latest FY) | $75.13M | $94.19B |
| Net income (latest FY) | -$146.41M | $26.80B |
| Net margin | -194.9% | 28.5% |
| P/E (trailing FY) | - | 21.6 |
| SEC filings | 297 | 984 |
JOHNSON & JOHNSON is 362.4x more valuable than AbCellera Biologics Inc. by market capitalization ($579.83 B vs $1.60 B).
In their latest fiscal years, AbCellera Biologics Inc. reported $75.13M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: AbCellera Biologics Inc. and JOHNSON & JOHNSON, or browse the full rankings.